Key facts
- This page summarizes Kimberly M. Murphy's Form 4 filing for Clarus Therapeutics Holdings, Inc..
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 09 Jun 2022, 20:04.
Kimberly M. Murphy - 07 Jun 2022 Form 4 Insider Report for Clarus Therapeutics Holdings, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 07 Jun 2022
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 09 Jun 2022, 20:04:31 UTC
- Prior SEC filing
- 27 May 2022
- Next SEC filing
- 24 Jun 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steven A. Bourne, attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Kimberly M. Murphy filed Form 4 for Clarus Therapeutics Holdings, Inc. on 09 Jun 2022.
Change
- Previous filing in this sequence was filed on 27 May 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CRXT
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +1,922
- Change %
- +50%
- Price
- $0.000000
- Shares after
- 5,766
- Date
- 07 Jun 2022
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CRXT
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +4,805
- Change %
- Price
- $0.000000
- Shares after
- 4,805
- Date
- 07 Jun 2022
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 4,805
- Exercise price
- $0.4339
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
The Reporting Person was granted a Restricted Stock Unit under the Issuer's 2021 Stock Option and Incentive Plan (the "2021 Plan") for 1,922 shares on 06/07/2022, which vests in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting.
Footnote F2
These options were granted under the 2021 Plan and vest in full at the earlier of June 7, 2023 or the next annual meeting subject to the Reporting Person having a service relationship as of each such vesting.